Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors

被引:31
|
作者
Cui, Jiahua [1 ]
Jia, Jinping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Shanghai, Peoples R China
关键词
Naphthoquinones; Juglone; M-pro inhibitors; SARS-CoV-2; COVID-19; NAPHTHOQUINONES; TOXICITY; DESIGN;
D O I
10.1016/j.ejmech.2021.113789
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
SARS-CoV-2 as a positive-sense single-stranded RNA coronavirus caused the global outbreak of COVID-19. The main protease (M-pro) of the virus as the major enzyme processing viral polyproteins contributed to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in drug discovery. Herein, a set of 1,4-naphthoquinones with juglone skeleton were prepared and evaluated for the inhibitory efficacy against SARS-CoV-2 Mpro. More than half of the tested naphthoquinones could effectively inhibit the target enzyme with an inhibition rate of more than 90% at the concentration of 10 mu M. In the structure-activity relationships (SARs) analysis, the characteristics of substituents and their position on juglone core scaffold were recognized as key ingredients for enzyme inhibitory activity. The most active compound, 2-acetyl-8-methoxy-1,4-naphthoquinone (15), which exhibited much higher potency in enzyme inhibitions than shikonin as the positive control, displayed an IC50 value of 72.07 +/- 4.84 nM towards M-pro- mediated hydrolysis of the fluorescently labeled peptide. It fit well into the active site cavity of the enzyme by forming hydrogen bonds with adjacent amino acid residues in molecular docking studies. The results from in vitro antiviral activity evaluation demonstrated that the most potent M-pro inhibitor could significantly suppress the replication of SARS-CoV-2 in Vero E6 cells within the low micromolar concentrations, with its EC50 value of about 4.55 mu M. It was non-toxic towards the host Vero E6 cells under tested concentrations. The present research work implied that juglone skeleton could be a primary template for the development of potent Mpro inhibitors. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Perspectives on SARS-CoV-2 Main Protease Inhibitors
    Gao, Kaifu
    Wang, Rui
    Chen, Jiahui
    Tepe, Jetze J.
    Huang, Faqing
    Wei, Guo-Wei
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955
  • [32] Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs
    Breidenbach, Julian
    Voget, Rabea
    Si, Yaoyao
    Hingst, Alexandra
    Claff, Tobias
    Sylvester, Katharina
    Wolf, Valentina
    Krasniqi, Vesa
    Useini, Abibe
    Straeter, Norbert
    Ogura, Yukino
    Kawaguchi, Atsushi
    Mueller, Christa E.
    Guetschow, Michael
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 8757 - 8790
  • [33] Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
    Puhl, Ana C.
    Godoy, Andre S.
    Noske, Gabriela D.
    Nakamura, Aline M.
    Gawriljuk, Victor O.
    Fernandes, Rafaela S.
    Oliva, Glaucius
    Ekins, Sean
    ACS OMEGA, 2023, 8 (25): : 22603 - 22612
  • [34] Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
    Kangsa Amporndanai
    Xiaoli Meng
    Weijuan Shang
    Zhenmig Jin
    Michael Rogers
    Yao Zhao
    Zihe Rao
    Zhi-Jie Liu
    Haitao Yang
    Leike Zhang
    Paul M. O’Neill
    S. Samar Hasnain
    Nature Communications, 12
  • [35] Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
    Amporndanai, Kangsa
    Meng, Xiaoli
    Shang, Weijuan
    Jin, Zhenmig
    Zhao, Yao
    Rao, Zihe
    Liu, Zhi-Jie
    Yang, Haitao
    Zhang, Leike
    O'Neill, Paul M.
    Hasnain, S. Samar
    Rogers, Michael
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [36] Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
    Acharya, Arpan
    Pandey, Kabita
    Thurman, Michellie
    Klug, Elizabeth
    Trivedi, Jay
    Sharma, Kalicharan
    Lorson, Christian L.
    Singh, Kamal
    Byrareddy, Siddappa N.
    JOURNAL OF VIROLOGY, 2021, 95 (24)
  • [37] Drug repurposing and computational modeling for discovery of inhibitors of the main protease (Mpro) of SARS-CoV-2
    Silva, Jose Rogerio A.
    Kruger, Hendrik G.
    Molfetta, Fabio A.
    RSC ADVANCES, 2021, 11 (38) : 23450 - 23458
  • [38] In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease
    Gao, Menghan
    Kang, Dongwei
    Liu, Na
    Liu, Yanna
    MOLECULES, 2023, 28 (14):
  • [39] In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database
    Muhtar, Eldar
    Wang, Mengyang
    Zhu, Haimei
    FUTURE VIROLOGY, 2021, 16 (08) : 507 - 518
  • [40] Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors
    Guo, Nihong
    Huang, Chong
    Qiao, Jingxin
    Li, Yueyue
    Wang, Yifei
    Xia, Anjie
    Zhang, Guo
    Fang, Zhen
    You, Jing
    Li, Linli
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 86